Updated Jul 16, 2026
Haviland Kate has filed 3 SEC Form 4 filings across 3 companies in the last 90 days — selling. Lifetime open-market sales: $227K.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-07-17 | BPMC | Blueprint Medicines Corp | J — Other acquisition / disposition | 70.7K | — | |
| 2025-07-17 | BPMC | Blueprint Medicines Corp | D — Derivative transaction | 224.4K | — | |
| 2025-07-17 | BPMC | Blueprint Medicines Corp | A — Grant or award | 129.2K | — | |
| 2024-12-03 | BPMC | Blueprint Medicines Corp | S — Open-market sale [10b5-1] | 207 | $97.76 | $20K |
| 2024-12-03 | BPMC | Blueprint Medicines Corp | S — Open-market sale [10b5-1] | 1.7K | $96.74 | $169K |
| 2024-12-03 | BPMC | Blueprint Medicines Corp | S — Open-market sale [10b5-1] | 400 | $95.40 | $38K |
Haviland Kate is a corporate insider — currently tracked as Insider of Fulcrum Therapeutics, Inc. (FULC). InsiderAlpha tracks every SEC Form 4 filing in real time.
3 primary Form 4 filings in the last 90 days, covering 3 companies.
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($227K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Haviland Kate profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.